

## Overview

### Useful For

[Establishing the diagnosis of an allergy to maleic anhydride](#)

[Defining the allergen responsible for eliciting signs and symptoms](#)

Identifying allergens:

- Responsible for allergic disease and/or anaphylactic episode

- To confirm sensitization prior to beginning immunotherapy

- To investigate the specificity of allergic reactions to insect venom allergens, drugs, or chemical allergens

Testing for IgE antibodies is **not useful** in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists, or in patients in whom the medical management does not depend upon identification of allergen specificity.

### Special Instructions

- [Allergens - Immunoglobulin E \(IgE\) Antibodies](#)

### Method Name

FluorescenceEnzymelImmunoassay(FEIA)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Ordering Guidance

[For a listing of allergens available for testing, see Allergens - Immunoglobulin E \(IgE\) Antibodies](#) in Special Instructions.

### Specimen Required

**Container/Tube:**

**Preferred:** Red top

**Acceptable:** Serum gel

**Specimen Volume:** 0.5 mL for every 5 allergens requested

### Forms

[If not ordering electronically, complete, print, and send an Allergen Test Request](#) (T236) with the specimen.

### Reject Due To

Gross hemolysis OK

Gross lipemia OK

### Specimen Minimum Volume

[For 1 allergen: 0.3 mL](#)

More than 1 allergen: (0.05 mL x number of allergens) + 0.25 mL dead space

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	14 days	
	Frozen	90 days	

## Clinical & Interpretive

### Clinical Information

Clinical manifestations of immediate hypersensitivity (allergic) diseases are caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE antibodies interact with allergen.

In vitro serum testing for IgE antibodies provides an indication of the immune response to allergen that may be associated with allergic disease.

The allergens chosen for testing often depend upon the age of the patient, history of allergen exposure, season of the year, and clinical manifestations. In individuals predisposed to develop allergic disease, the sequence of sensitization and clinical manifestations proceed as follows: eczema and respiratory disease (rhinitis and bronchospasm) in infants and children <5 years due to food sensitivity (milk, egg, soy, and wheat proteins) followed by respiratory disease (rhinitis and asthma) in older children and adults due to sensitivity to inhalant allergens (dust mite, mold, and pollen inhalants).

### Reference Values

Class	IgE kU/L	Interpretation
0	<0.35	Negative
1	0.35-0.69	Equivocal
2	0.70-3.49	Positive
3	3.50-17.4	Positive
4	17.5-49.9	Strongly positive
5	50.0-99.9	Strongly positive
6	> or =100	Strongly positive

### Interpretation

Detection of IgE antibodies in serum (Class 1 or greater) indicates an increased likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be responsible for eliciting signs and symptoms.

The level of IgE antibodies in serum varies directly with the concentration of IgE antibodies expressed as a class score or kU/L.

### Cautions

Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies in serum, and results must be interpreted in the clinical context.

False-positive results for IgE antibodies may occur in patients with markedly elevated serum IgE (>2500 kU/L) due to nonspecific binding to allergen solid phases.

---

**Clinical Reference**

Homburger HA, Hamilton RG: Allergic diseases. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. Elsevier; 2017:1057-1070

**Performance****Method Description**

[Specific IgE from the patient's serum reacts with the allergen of interest, which is covalently coupled to an ImmunoCAP. After washing away nonspecific IgE, enzyme-labeled anti-IgE antibody is added to form a complex. After incubation, unbound anti-IgE is washed away, and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. Fluorescence is proportional to the amount of specific IgE present in the patient's sample \(ie, the higher the fluorescence value, the more IgE antibody is present\).](#)(Package insert: [ImmunoCAP System Specific IgE FEIA. Phadia; Rev 06/2019](#))

**PDF Report**

No

**Specimen Retention Time**

14 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Test Classification**

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

86003